IN2012DN01231A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01231A IN2012DN01231A IN1231DEN2012A IN2012DN01231A IN 2012DN01231 A IN2012DN01231 A IN 2012DN01231A IN 1231DEN2012 A IN1231DEN2012 A IN 1231DEN2012A IN 2012DN01231 A IN2012DN01231 A IN 2012DN01231A
- Authority
- IN
- India
- Prior art keywords
- jnk
- compounds
- disclosed
- compositions
- formulations
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000012825 JNK inhibitor Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23252209P | 2009-08-10 | 2009-08-10 | |
| PCT/EP2010/061476 WO2011018417A1 (en) | 2009-08-10 | 2010-08-06 | Inhibitors of jnk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN01231A true IN2012DN01231A (enExample) | 2015-05-15 |
Family
ID=42710723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1231DEN2012 IN2012DN01231A (enExample) | 2009-08-10 | 2010-08-06 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8536172B2 (enExample) |
| EP (1) | EP2464640A1 (enExample) |
| JP (1) | JP5784604B2 (enExample) |
| KR (1) | KR101506318B1 (enExample) |
| CN (1) | CN102471319B (enExample) |
| AR (1) | AR077820A1 (enExample) |
| AU (1) | AU2010283769B2 (enExample) |
| BR (1) | BR112012003059A2 (enExample) |
| CA (1) | CA2768749A1 (enExample) |
| IL (1) | IL217756A0 (enExample) |
| IN (1) | IN2012DN01231A (enExample) |
| MX (1) | MX2012001449A (enExample) |
| SG (1) | SG178321A1 (enExample) |
| TW (1) | TW201109336A (enExample) |
| WO (1) | WO2011018417A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2012155144A (ru) * | 2010-06-04 | 2014-07-20 | Ф. Хоффманн-Ля Рош Аг | Ингибиторы jnk |
| KR101862912B1 (ko) | 2012-07-20 | 2018-05-30 | 클리브 바이오사이언스 인코포레이티드 (클리브) | p97 복합체의 저해제로서의 축합된 피리미딘 |
| US10624948B2 (en) * | 2013-06-26 | 2020-04-21 | Xigen Inflammation Ltd. | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
| DK3126352T3 (en) * | 2014-04-04 | 2019-01-21 | Syros Pharmaceuticals Inc | CYCLINE INDEPENDENT KINASE 7 INHIBITORS (CDK7) |
| ES2985135T3 (es) | 2014-12-18 | 2024-11-04 | Harvard College | Procedimientos para generar células ß derivadas de células madre y usos de las mismas |
| CN107567453A (zh) * | 2015-03-13 | 2018-01-09 | 艾伯维公司 | (吲唑‑4‑基)六氢吡咯并吡咯酮类及使用方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5325783B2 (ja) * | 2006-09-08 | 2013-10-23 | エフ．ホフマン−ラ ロシュ アーゲー | ベンゾトリアゾールキナーゼモジュレーター |
| JP5179509B2 (ja) * | 2006-12-08 | 2013-04-10 | エフ．ホフマン−ラ ロシュ アーゲー | 置換ピリミジン類及びｊｎｋモジュレーターとしてのこれらの使用 |
-
2010
- 2010-08-06 JP JP2012524207A patent/JP5784604B2/ja not_active Expired - Fee Related
- 2010-08-06 WO PCT/EP2010/061476 patent/WO2011018417A1/en not_active Ceased
- 2010-08-06 KR KR1020127006275A patent/KR101506318B1/ko not_active Expired - Fee Related
- 2010-08-06 SG SG2012008819A patent/SG178321A1/en unknown
- 2010-08-06 EP EP10739948A patent/EP2464640A1/en not_active Withdrawn
- 2010-08-06 CN CN201080035300.3A patent/CN102471319B/zh not_active Expired - Fee Related
- 2010-08-06 IN IN1231DEN2012 patent/IN2012DN01231A/en unknown
- 2010-08-06 CA CA2768749A patent/CA2768749A1/en not_active Abandoned
- 2010-08-06 AU AU2010283769A patent/AU2010283769B2/en not_active Ceased
- 2010-08-06 MX MX2012001449A patent/MX2012001449A/es active IP Right Grant
- 2010-08-06 BR BR112012003059A patent/BR112012003059A2/pt not_active IP Right Cessation
- 2010-08-09 US US12/852,540 patent/US8536172B2/en not_active Expired - Fee Related
- 2010-08-09 AR ARP100102908A patent/AR077820A1/es unknown
- 2010-08-09 TW TW099126517A patent/TW201109336A/zh unknown
-
2012
- 2012-01-26 IL IL217756A patent/IL217756A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2768749A1 (en) | 2011-02-17 |
| US20110034470A1 (en) | 2011-02-10 |
| JP2013501746A (ja) | 2013-01-17 |
| CN102471319B (zh) | 2014-06-18 |
| CN102471319A (zh) | 2012-05-23 |
| AU2010283769A1 (en) | 2012-02-09 |
| WO2011018417A1 (en) | 2011-02-17 |
| US8536172B2 (en) | 2013-09-17 |
| MX2012001449A (es) | 2012-03-26 |
| AR077820A1 (es) | 2011-09-28 |
| IL217756A0 (en) | 2012-03-29 |
| AU2010283769B2 (en) | 2015-09-17 |
| TW201109336A (en) | 2011-03-16 |
| KR20120055645A (ko) | 2012-05-31 |
| BR112012003059A2 (pt) | 2016-08-02 |
| KR101506318B1 (ko) | 2015-03-26 |
| JP5784604B2 (ja) | 2015-09-24 |
| EP2464640A1 (en) | 2012-06-20 |
| SG178321A1 (en) | 2012-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200744586A (en) | Therapeutic compounds | |
| MX2011007750A (es) | Composiciones y metodos para inhibicion de la ruta jak. | |
| MX348024B (es) | Compuestos de adamantilo. | |
| MX2009006195A (es) | Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso. | |
| MX2009013353A (es) | Compuestos activadores de telomerasa y metodos para su uso. | |
| PH12012502212A1 (en) | Nitrogen heterocyclic compounds usefulas pde10 inhibitors | |
| MX2020009397A (es) | Composiciones y metodos para inhibicion de la via jak. | |
| MX2009011754A (es) | Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1. | |
| MX2012002633A (es) | Aminotetrahidropiranos como inhibidores de la dipeptidil peptidasa iv para el tratamiento prevencion de la diabetes. | |
| MX337190B (es) | Nuevas bencensulfonamidas como bloqueadores del canal de calcio. | |
| MY153057A (en) | Tryclic compounds,compositions and methods | |
| MX367623B (es) | 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3. | |
| WO2010124121A8 (en) | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitor | |
| MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
| TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
| MX2012001134A (es) | Composiciones y metodos para inhibicion de la via jak. | |
| MX2009011753A (es) | Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1. | |
| IN2012DN03846A (enExample) | ||
| IN2012DN01231A (enExample) | ||
| WO2011047055A8 (en) | Novel mek inhibitors, useful in the treatment of diseases | |
| WO2006093547A3 (en) | Novel lipoxygenase inhibitors | |
| MX2014000374A (es) | Compuesto de aminometil quinolona. | |
| MX342119B (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| PH12012501636A1 (en) | 2-((r)-2- methylpyrrolidin -2-yl) -1h- benzimidazole -4- carboxamide crystalline form 1 | |
| WO2010065861A3 (en) | Inhibitors of bace 1 and methods for treating alzheimer's disease |